Wednesday, September 19, 2018
 
 
Company News: Page (1) of 1 - 06/19/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Medibio Receives TGA Approval

(June 19, 2018)

SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company,  announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform.

The Company’s regulatory validation now includes both the CE (Conformité Européenne) Mark and Therapeutic Good Administration (TGA) under the GMDN product code 58290 - Psychological assessment system application software.

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information:  Website: www.medibio.com.au
 
Shareholder and Investor Inquiries:
Stephanie Ottens
Investor Relations Director
Medibio Limited
[email protected]
T: +61 434 405 400
 Media Inquiries:
Josh Purdy
Senior Public Relations Manager
Medibio Limited
[email protected]
T: +1 952-222-0551 ext. 208
M: +1 612-695-0168

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • ChenMed to Invest More Than $200 Million to Bring Affordable Concierge-Style Health Care to Philadelphia Seniors
  • Consuelo M. Alvarez, M.D., MBA, is recognized by Continental Who's Who
  • IV Infusion Pump Accessories Market is poised to register a CAGR of 4.5% by 2025 – Persistence Market Research
  • Effie Chow Qigong Healing System Available On Mediterranean Celebrity Cruise Line Says Sharon Kleyne & Rose Hong
  • The Methuselah Foundation Successfully Closes its Boutique Venture Fund, the Methuselah Fund, Focused on Companies That Can Extend the Healthy Human Lifespan

    Cancer
  • Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society
  • BioPlus Specialty Pharmacy Announces New President: Mark Montgomery
  • Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US
  • Chardan Advises NovellusDX in Cross-Border Biotech Merger
  • Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines